Breaking News
Get 45% Off 0
Investors lost 37% by missing this ONE signal 😵
Read now

Stock Markets Analysis & Opinion

Contribute
Zacks Investment Research
Is Leucadia National (LUK) A Great Stock For Value Investors? By Zacks Investment Research - Nov 06, 2017

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are...

Zacks Investment Research
What's In Store For Johnson Controls (JCI) In Q4 Earnings? By Zacks Investment Research - Nov 06, 2017

Johnson Controls International plc (NYSE:JCI) is set to report fourth-quarter and full-year 2017 results on Nov 9, before market open.Last quarter, the company reported in-line results. In fact, the...

Zacks Investment Research
Deutsche Bank Shows Capital Strength, Legal Costs A Drag By Zacks Investment Research - Nov 06, 2017

On Nov 6, we issued an updated research report on Deutsche Bank AG (DE:DBKGn) (NYSE:DB) . Its initiatives to improve performance through expense management and strengthening capital position will...

Zacks Investment Research
MoneyGram (MGI) Q3 Earnings Beat, Revenues Miss Estimates By Zacks Investment Research - Nov 06, 2017

MoneyGram International Inc. (NASDAQ:MGI) reported earnings of 24 cents per share, which surpassed the Zacks Consensus Estimate by 4.4% but decreased 4% year over year.Total revenues of $397.8...

Zacks Investment Research
Tapestry (TPR) Q1 Earnings Beat, Sales Miss, Retains View By Zacks Investment Research - Nov 06, 2017

Despite tough retail landscape, Tapestry, Inc. (NYSE:TPR) posted better-than-expected first-quarter fiscal 2018 bottom-line results. The adjusted earnings of 42 cents a share beat the Zacks...

Zacks Investment Research
Royal Caribbean (RCL) Tops Q3 Earnings, Revenues Lag By Zacks Investment Research - Nov 06, 2017

Royal Caribbean Cruises Ltd. (NYSE:RCL) operates as a global cruise and vacation company. Given the strength and diversity of its brands and itineraries, this cruise operator has successfully...

Zacks Investment Research
Barclays (BCS) Fails To Get Rid Of Dark Pool Class Action By Zacks Investment Research - Nov 06, 2017

Barclays (LON:BARC) PLC (NYSE:BCS) was unsuccessful in convincing the U.S. appeals court to undo the class action lawsuit that accused it of cheating its shareholders with regard to the private...

Zacks Investment Research
Keryx (KERX) Posts Wider Q3 Loss, Lags Sales, Shares Down By Zacks Investment Research - Nov 06, 2017

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) ) is a Boston-based biopharmaceutical company working in the field of renal diseases.The company’s only product is Auryxia (ferric citrate) which is...

Zacks Investment Research
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss By Zacks Investment Research - Nov 06, 2017

Endocyte, Inc. (NASDAQ:ECYT) incurred a loss of 27 cents per share in third-quarter 2017 narrower than the Zacks Consensus Estimate of a loss of 35 cents. However, the figure came in wider than the...

Zacks Investment Research
Let's Make A Deal...and Some New Highs By Zacks Investment Research - Nov 06, 2017

Remember, the latest episode of the Zacks Ultimate Strategy Session will be available for viewing no later than Wednesday, November 8th. Sheraz Mian, David Bartosiak, Tracey Ryniec, Brian Bolan and...

Zacks Investment Research
Tech Stocks Earnings Due On Nov 8: SQ, GIB, DOX And PEGA By Zacks Investment Research - Nov 06, 2017

We are approaching the end of the third-quarter reporting cycle, with 406 S&P 500 members or 85.4% of the index’s total membership having already reported their numbers, as of Nov 3,...

Zacks Investment Research
Ionis (IONS) Beats On Q3 Earnings, Revenues Miss By Zacks Investment Research - Nov 06, 2017

Carlsbad, CA-based Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies....

Zacks Investment Research
Envision Healthcare Hits 52-Week Low On Q3 Loss, Grim View By Zacks Investment Research - Nov 06, 2017

Shares of Envision Healthcare Corp. (NYSE:EVHC) tumbled to a 52-week low of $26.34 during the trading session on Nov 6. The slide is believed to have been driven by poor third-quarter results and a...

Zacks Investment Research
Welltower (HCN) Surpasses Q3 FFO And Revenues Estimates By Zacks Investment Research - Nov 06, 2017

Have you been eager to see how Welltower Inc. (NYSE:HCN) performed in Q3 in comparison with the market expectations? Let’s quickly scan through the key facts from this Toledo, OH-based,...

Continue with Apple
Continue with Google
or
Sign up with Email